Mesoblast Limited clinical trials

The registry lists 40 studies whose lead sponsor is Mesoblast Limited or one of 2 companies grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 17, 2026.

Studies

Recruiting first, then most recently updated. Showing 40 of 40.

• A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host DiseaseNot yet recruitingNCT07568535Phase 3

  Sponsor listed in the registry: Mesoblast, Ltd.

• Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back PainActive, not recruitingNCT06325566Phase 3

  Sponsor listed in the registry: Mesoblast, Ltd.

• Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart FailureCompletedNCT02032004Phase 3

  Sponsor listed in the registry: Mesoblast, Inc.

• Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's DiseaseCompletedNCT00482092Phase 3

  Sponsor listed in the registry: Mesoblast, Inc.

• Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's DiseaseCompletedNCT01233960Phase 3

  Sponsor listed in the registry: Mesoblast, Inc.

• PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)CompletedNCT00690066Phase 2

  Sponsor listed in the registry: Mesoblast, Inc.

• Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's DiseaseCompletedNCT00543374Phase 3

  Sponsor listed in the registry: Mesoblast, Inc.

• PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00683722Phase 2

  Sponsor listed in the registry: Mesoblast, Inc.

• Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)CompletedNCT00877903Phase 2

  Sponsor listed in the registry: Mesoblast, Inc.

• Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)No longer availableNCT04456439

  Sponsor listed in the registry: Mesoblast International Sàrl

• Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD ParticipantsCompletedNCT00284986Phase 2

  Sponsor listed in the registry: Mesoblast, Inc.

• Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back PainCompletedNCT02412735Phase 3

  Sponsor listed in the registry: Mesoblast, Ltd.

• Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial InfarctionCompletedNCT01781390Phase 2

  Sponsor listed in the registry: Mesoblast, Inc.

• A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)CompletedNCT02336230Phase 3

  Sponsor listed in the registry: Mesoblast, Inc.

• Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHDCompletedNCT02652130Phase 3

  Sponsor listed in the registry: Mesoblast, Inc.

• Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)CompletedNCT00366145Phase 3

  Sponsor listed in the registry: Mesoblast, Inc.

• Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)CompletedNCT00136903Phase 2

  Sponsor listed in the registry: Mesoblast, Inc.

• Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)CompletedNCT00562497Phase 3

  Sponsor listed in the registry: Mesoblast, Inc.

• Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following MeniscectomyCompletedNCT00702741Phase 1/2

  Sponsor listed in the registry: Mesoblast International Sàrl

• A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following MeniscectomyCompletedNCT00225095Phase 1/2

  Sponsor listed in the registry: Mesoblast International Sàrl

• Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 InfectionNo longer availableNCT04366830

  Sponsor listed in the registry: Mesoblast International Sàrl

• Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody FusionCompletedNCT00996073Phase 2

  Sponsor listed in the registry: Mesoblast, Ltd.

• Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and FusionCompletedNCT01106417Phase 1/2

  Sponsor listed in the registry: Mesoblast, Ltd.

• Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)CompletedNCT00549913Phase 1/2

  Sponsor listed in the registry: Mesoblast, Ltd.

• Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back PainCompletedNCT01290367Phase 2

  Sponsor listed in the registry: Mesoblast, Ltd.

• P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic MalignanciesCompletedNCT01854567Phase 3

  Sponsor listed in the registry: Mesoblast, Ltd.

• A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα InhibitorCompletedNCT01851070Phase 2

  Sponsor listed in the registry: Mesoblast, Ltd.

• Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar FusionWithdrawnNCT00810212Phase 1/2

  Sponsor listed in the registry: Mesoblast, Ltd.

• Safety Study of Mesenchymal Precursor Cells in Type 2 DiabetesCompletedNCT01576328Phase 1/2

  Sponsor listed in the registry: Mesoblast, Ltd.

• Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's DiseaseCompletedNCT00294112Phase 2

  Sponsor listed in the registry: Mesoblast, Inc.

• A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart FailureCompletedNCT00721045Phase 2

  Sponsor listed in the registry: Mesoblast, Ltd.

• Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's DiseaseNo longer availableNCT01510431

  Sponsor listed in the registry: Mesoblast, Inc.

• Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial InfarctionCompletedNCT00114452Phase 1

  Sponsor listed in the registry: Mesoblast, Inc.

• Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)No longer availableNCT00826046

  Sponsor listed in the registry: Mesoblast, Inc.

• Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHDNo longer availableNCT00759018

  Sponsor listed in the registry: Mesoblast, Inc.

• Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical DiscectomyCompletedNCT01097486Phase 2

  Sponsor listed in the registry: Mesoblast, Ltd.

• Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament ReconstructionCompletedNCT01088191Phase 1/2

  Sponsor listed in the registry: Mesoblast, Ltd.

• Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic NephropathyCompletedNCT01843387Phase 1/2

  Sponsor listed in the registry: Mesoblast, Ltd.

• OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic MalignanciesWithdrawnNCT00081055Phase 2

  Sponsor listed in the registry: Mesoblast International Sàrl

• Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial InfarctionStatus unknownNCT00555828Phase 1/2

  Sponsor listed in the registry: Angioblast Systems · First submitted before Angioblast Systems became part of Mesoblast Limited